|Mr. David Budd||CEO & Exec. Director||242.19k||N/A||1968|
|Mr. Russell John Shaw||Chief Financial Officer & Director||N/A||N/A||1979|
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
genedrive plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.